Active Ingredient History

NOW
  • Now
Zosuquidar is an experimental antineoplastic drug. In 2010, it was announced that a phase III trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome did not meet its primary endpoint and Eli Lilly discontinued its development.   Wikipedia

  • SMILES: O[C@@H](COc1cccc2ncccc12)CN3CCN(CC3)[C@H]4c5ccccc5[C@H]6[C@@H](c7ccccc47)C6(F)F
  • InChIKey: IHOVFYSQUDPMCN-DBEBIPAYSA-N
  • Mol. Mass: 527.62
  • ALogP: 5.21
  • ChEMBL Molecule:
More Chemistry
zosuquidar

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue